



REVIEW

Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review

Mengyuan Li^{1*}, Minghuan Zhang^{1*}, Qian Ye², Yunhua Liu³, Wenbin Qian¹

¹Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China; ²Hangzhou Rong-Gu Biotechnology Limited Company, Hangzhou 310056, China; ³Department of Pathology & Pathophysiology and Department of Surgical Oncology of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China

ABSTRACT

Oncolytic virotherapy has emerged as a promising treatment for human cancers owing to an ability to elicit curative effects *via* systemic administration. Tumor cells often create an unfavorable immunosuppressive microenvironment that degrade viral structures and impede viral replication; however, recent studies have established that viruses altered *via* genetic modifications can serve as effective oncolytic agents to combat hostile tumor environments. Specifically, oncolytic vaccinia virus (OVV) has gained popularity owing to its safety, potential for systemic delivery, and large gene insertion capacity. This review highlights current research on the use of engineered mutated viruses and gene-armed OVVs to reverse the tumor microenvironment and enhance antitumor activity *in vitro* and *in vivo*, and provides an overview of ongoing clinical trials and combination therapies. In addition, we discuss the potential benefits and drawbacks of OVV as a cancer therapy, and explore different perspectives in this field.

KEYWORDS

Oncolytic virotherapy; oncolytic vaccinia virus; engineered virus; arming strategy

Introduction

Over the last decade research attention has shifted from cancer cells to the tumor microenvironment (TME) given that approximately 95% of cancer cases stem from the environment and lifestyle¹. Cancer cells exist and continue to thrive within the TME, which is comprised of cancer and non-cancerous host cells (such as immune cells), microvessels, and various cytokines and chemokines. Interactions between tumor cells and the TME have crucial roles in tumor development, progression, metastasis, and therapeutic responses^{1,2}. The success of emerging immunotherapies indicates that the most promising approach is harnessing the immune system

to fight against cancer³. There are several types of immunotherapy, including immune checkpoint inhibitors (ICIs), chimeric antigen receptor T (CAR-T) cell therapy, bacterial therapy, and oncolytic virotherapy. ICIs include antibodies, ligands, and Fc-fused proteins that interact with innate and adaptive immune receptors, such as PD-1/PD-L1, CTLA-4, TIM-3, LAG-3, TIGIT, CD47, and SIRP α . ICIs have shown promise in the treatment of several types of cancer; however, monotherapy is unlikely to yield long-term benefits for most patients due to severe immune-related adverse events⁴⁻⁶. CAR-T cell therapy involves arming modified T cells that navigate to target cancer cells *via* CD19 and BCMA. This method is particularly effective for the treatment of haematologic malignancies; however, the effectiveness against solid tumors has been limited. Therefore, new therapeutic strategies are needed to overcome this resistance.

Oncolytic viruses (OVs) are an attractive therapeutic strategy. In general, oncolytic virotherapy benefits from tumor cell selective replication and oncolysis, which lead to a chain reaction of immune activation. Serving as a therapeutic vector that delivers exogenous therapeutic genes to amplify anti-tumor responses and restore anti-tumor immunity, which reprograms the TME by various

*These authors contributed equally to this work.

Correspondence to: Yunhua Liu and Wenbin Qian
E-mail: yunhualiu@zju.edu.cn and qianwb@zju.edu.cn
ORCID ID: <https://orcid.org/0000-0002-2631-795X>
and <https://orcid.org/0000-0002-9817-6674>

Received June 12, 2023; accepted July 19, 2023;
published online August 23, 2023.

Available at www.cancerbiomed.org

©2023 Cancer Biology & Medicine. Creative Commons Attribution-NonCommercial 4.0 International License

mechanisms is another advantage. This armed OV strategy has been successfully tested in preclinical studies and clinical trials. For example, OV can be armed with cytokines, chemokines, monoclonal antibodies, bispecific antibodies, ligands, enzymes, and suicide genes. These therapeutic genes are mainly involved in immune activation, immune stimulation, and cell metabolism. To date, only the herpes simplex virus type 1 OV, talimogene laherparepvec (T-VEC), has been approved by the U.S. Food & Drug Administration^{7,8}. Several virus species, including adenovirus, herpes simplex virus, and vaccinia virus, have been designed for immunotherapy⁹; however, safety concerns regarding OVs that can infect healthy cells or cause unintended side effects have limited clinical application. Because of the different structures and physiologic features, OVs have dissimilar abilities to dissolve tumors, induce immune responses, and capabilities to insert foreign genes¹⁰. Compared to RNA viruses, DNA viruses, such as vaccinia virus (VV), have larger and more complete genomes, making DNA viruses easier to manipulate and pack larger transgenes¹¹. **Table 1** summarizes the strengths and shortcomings of VV and other OVs. VV has been utilized as a smallpox vaccine by the World Health Organization since 1976, thus there is significant experience and in-depth clinical knowledge of the vaccine¹². As of 2023, there have been approximately 30 reported clinical trials involving the oncolytic vaccinia virus (OVV) for the treatment of melanoma, and ovarian, colorectal, and hepatocellular carcinomas, with > 1500 cancer patients treated. In this study we provide an overview of different OVV strains and mutations in multiple transgenes that have reversed the immunosuppressive TME in a series of preclinical studies and related clinical trials. In addition, reciprocal inhibition between cancer cells and the OVV within the TME is discussed.

Improvement of tumor cell immunogenicity within the TME

OVV directly increases tumor cell immunogenicity

Generating an effective immune response against tumors is challenging because of the limited number of tumor antigens and low immunogenicity, especially among 'cold' tumors. These features present significant barriers to successful cancer immunotherapy. OVVs selectively infect tumor cells and replicate continuously, thus causing oncolysis¹³. The viral progeny released from disrupted tumor cells infect peripheral tumor cells, leading to a positive chain-like infection that produces a long-lasting anti-tumor effect¹⁴. When OVVs infect tumor cells, tumor-associated molecular patterns are exposed^{15,16}, such as tumor-associated antigens (TAAs), danger signals (DAMPs), PAMPs, and cytokines, which trigger local immune responses. Additionally, tumor-associated molecular patterns stimulate innate and adaptive immunity at distal tumor sites that are not directly injected by the virus¹⁷.

Several mechanisms promote cancer cell death in the TME. OVV-white-spotted char lectin (WCL) promotes tumor cell apoptosis through the activation of caspase-3 and cleaved caspase-9, increases the level of interferon expression, and inhibits tumor growth *in vivo*¹⁸. Furthermore, OVVs have been modified to include genes that promote apoptosis, such as second mitochondria-derived activator of caspase (SMAC) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). These modifications increase cytotoxicity and induce apoptosis in pancreatic cancer tissues, as well as other cancer models¹⁹⁻²¹. Recently, we developed an OVV expressing the autophagic gene Beclin-1 (named OVV-BECN1).

Table 1 Characteristics of VV and other OVs

Virus	VV	Adenovirus	Herpes simplex virus	Coxsackievirus
Genome	dsDNA(~200 kb)	dsDNA(30–40 kb)	dsDNA(~152 kb)	(+)ssRNA(~7.4 kb)
Genome capacity	25–40 kb	7–8 kb	30–40 kb	300 bases
Cell entry mechanism	Membrane penetration and fusion	Endocytosis	Endocytosis; penetration	Micropinocytosis
Replication site	Cytoplasm	Nucleus	Nucleus	Cytoplasm
Risk of integration	No	More risk	More risk	No
Immunogenicity	High	Low	Low	Low

After OVV-BECN1 infection, translated Beclin-1 activates downstream signalling molecules, resulting in autophagosome formation and the induction of autophagic cell death. It has a favourable therapeutic effect in leukemia and multiple myeloma models²². Additionally, an OVV expressing the *FCU-1* suicide gene, TG6002, catalyses the conversion of 5-fluorocytosine (5-FC) to 5-fluorouracil and has shown significant antitumor activity, especially when used in combination with external 5-FC administration²³.

In the immunosuppressive TME, the upregulated expression levels of suppressive cytokines impedes antitumor immunity and impairs the efficacy of ICIs in clinical settings²⁴. To this end, OVVs expressing ICIs may increase tumor immunogenicity and reverse immunosuppressive signals within the TME. For instance, an engineered OVV carrying a gene encoding a full anti-TIGIT antibody was developed to suppress immune responses activated by single-agent OV treatment. Using mouse models, vaccinia virus- α -TIGIT demonstrated efficacious antitumor immunity, long-term efficacy, and the establishment of immunological memory involving CD8+ T cells and natural killer (NK) cells²⁵. Similarly, our research group conducted a preliminary study showing that an engineered OVV expressing an anti-CD47 nanobody improves efficacy against lymphoma by promoting macrophage phagocytosis of CD47+ tumors and NK-cell-mediated antibody-dependent cellular cytotoxicity. Another group obtained similar results using herpes simplex virus²⁶. These studies underscore the potential of OVV as a promising vector to turn 'cold' tumors into 'hot' tumors by promoting the infiltration of immune cells²⁷.

OVVs indirectly increase tumor cell immunogenicity

Despite the infiltration of immune cells and pro-inflammatory cytokines into immune-desert cold tumors, the tumors remain immune-resistant²⁸. The effect of cytokines on immune cells depends on the properties, concentration, and environment; cytokines may either activate or inhibit immune cells²⁹. OVVs bearing cytokines, such as GM-CSF, IL-2, IL-6, IL-12, IL-15, IL-23, and IL-24, have demonstrated exceptional anti-cancer effects and remarkable safety in clinical and pre-clinical evaluations. EphA2-TEA-OVV, which expresses a bispecific T cell engager targeting CD3, EphA2, or EpCAM, exhibits notable anti-tumor activity and bystander killing of non-infected tumor cells^{30,31}. Our team developed an OVV

encoding a bispecific T cell engager (OVV-CD19BiTE) that activates and induces memory T cell differentiation, which led to an effective treatment of B-cell lymphoma³².

The combination of OVVs and hormonal factors is a promising approach for cancer therapy. Prostaglandin E2 (PGE2), a vital homeostatic hormone, is a key mediator in cancer immunity. The COX-2/PGE2 axis contributes to the development of therapeutic resistance and inhibits immune activation in the TME. Targeting PGE2 using OVV-engineered hydroxy prostaglandin dehydrogenase 15 (15-HPGD) or the COX-2 inhibitor, celecoxib, reverses the immunosuppressive state and reduces the number of immunosuppressive cells in the TME, which leads to improved therapeutic outcomes³³. Another recent study revealed that an OVV engineered to express leptin, which functions as a metabolic modulator, alters the status of T cells in the TME. Environmental leptin enhances mitochondrial function and the oxidative phosphorylation of tumor-infiltrating T cells, thus providing metabolic support for these immune cells³⁴. This study on the combination of an OVV and hormonal factors shed new light on OV therapy and suggested that metabolic reprogramming, rather than solely the influx of specific immune cells into the TME, may play a superior role in inhibiting tumor growth.

Enhanced OVV durability and selectivity to overcome the immunosuppressive TME

Characteristics of VV

Several biological characteristics of VV make it an excellent viral platform for cancer immunotherapy. First, VV is a large enveloped virus with a linear double-stranded 190-kb DNA genome that encodes approximately 250 genes, but can accommodate up to 50 kb of transgenes³⁵. Second, VV requires host cells for replication, and the replication cycle is dependent on a high-fidelity DNA polymerase, which ensures the integrity of the viral genome³⁶. Third, the virus replicates exclusively in the cytoplasm³⁷, thus minimising the risk of viral DNA integration into the host genome and making it an excellent OV candidate. Fourth, compared to other OVVs, the VV has some advantages, such as rapid replication (progeny viruses can be produced in 6 h)³⁸, broad tumor tropism, and the ability to replicate without limitations under hypoxic conditions. Fifth, VV infection prompts immune responses without causing

significant disease in healthy individuals. The vast amount of data on the long-term use of VV vaccines provides a strong safety foundation for clinical application. Antiviral drugs can be used to manage the potential adverse effects^{39,40}. Sixth, even if patients receive a VV or produce neutralising antibodies, the virus can still effectively infect the tumor *via* intravenous injection. Finally, the virus has three transmission mechanisms: cell-to-cell spread⁴¹, extracellular enveloped virus release⁴², and repulsion of superinfecting virions⁴³. Of note, the details of these complex mechanisms are not well understood. **Figure 1** depicts the VV life cycle, with a diagram of infected cells and the important viral proteins involved in virus formation and transmission.

Strategy for the modification of OVVs

An unmodified VV has the ability to kill tumor cells, but the clinical application is limited due to its side effects, such as hepatitis and fatal neuroencephalitis, as reported in historical clinical data from the 1980s⁴⁴. To improve clinical efficacy, modifications have been made to the virus with the goal of better tumor cell selectivity, stronger target gene expression, higher

therapeutic effects, lower toxicity, and less immunogenicity. As shown in **Table 2**, vaccinia vectors used for oncolytic utilities mainly include the Wyeth⁴⁵, Western reserve (WR)⁴⁶, Lister⁴⁷, Copenhagen²³, New York City Board of Health (NYCBH)⁴⁸, and Tiantan (TTV) strains⁴⁹. Thymidine kinase (TK) is the most commonly deleted gene. TK is one of the key enzymes for the synthesis of VV DNA. Deletion of the *J2R* gene (encoding TK) makes VV a tumor-selective cloning and expression vector, and VV has been further confirmed to be associated with decreased virulence of recombinant VVs, such as Pexa-Vec. VV is an extracellular enveloped virus (EEV) that contains a host-derived outer membrane and B5R protein, which can be recognised by the complement system and results in EEV neutralisation⁵⁰⁻⁵². Partial deletion of short consensus repeats in the *B5R* gene increases neutralisation escape, without affecting the oncolytic potency of the VV, making VV resistant to immune clearance and improving therapeutic outcomes⁴⁹.

Given the complex interactions between the immune system and OVV, a single disruption of *J2R* may not be sufficient. Thus, double-, triple-, and quadruple-deletion mutant VVs have been generated. *I4L* encodes a large subunit of ribonucleotide reductase (RR). The *J2R*- and *I4L*-mutant virus, TG6002,




Figure 1 The life cycle of VV and major viral proteins involved in virus formation and transmission. The virus forms a fusion protein complex that consists of eight viral proteins (A16, A21, A28, G3, G9, H2, J5, and L5), then enters the cell interior. IMV, as an infectious form, has A17L, A27L, and D8L to help adhere to the surface of the cell membrane. VV replication and progeny assembly occur in the “poxvirus factory” of the cytoplasm of infected cells. IMV is transported to the extracellular space through microtubules, while fusing with the cell membrane to form CEV. CEV encodes genes (A33R, A34R, A36R, A56R, B5R, and F13L), thus forming EEV for intercellular transmission and distant metastasis. IMV can also be encapsulated by the Golgi complex to form IEV, which is then transported to the periphery of cells mediated by F12L and A36R. IMV, intracellular mature virus; CEV, cell-associated enveloped virus; EEV, extracellular enveloped virus; IEV, intracellular enveloped virus.

Table 2 Oncolytic vaccinia virus strains and mutations studied for cancer treatment

Strain	Modification	Representative viruses	Insertions (Ref)
Wyeth	<i>J2R</i> -	Pexa-vec	GM-CSF ⁴⁵
WR	<i>J2R</i> -, <i>VGF</i> -	wDD	GFP ⁴⁶
Lister	<i>J2R</i> -, <i>F14.5L</i> -, <i>A56R</i> -	GL-ONC1	Renilla luciferase-GFP fusion protein, β -galactosidase, β -glucuronidase ⁷⁴
	<i>VGF</i> -, <i>O1L</i> -	ASP9801	IL-7/IL12 ⁵⁷
Tian Tan Guang 9	<i>J2R</i> -	VG9	GM-CSF; IL-24 ⁹⁵
Copenhagen	<i>J2R</i> -, <i>I4L</i> -	TG-6002	FCU-1 ²³
New York City Board of Health	5p, 3p, and B14R	vaccinia virus-aCEA TCE	aCEA T cell engagers ²⁹

exhibits uninfluenced tumor-selective replication, tumor cell killing, and highly-attenuated virulence in healthy cells compared to the single TK-deleted version²³. Similarly, the deletion of *F4L*, the gene encoding the small subunits of RR,⁵³ and *J2R* yield similar results⁵⁴. Pelin et al.⁵⁵ generated an OVV by deleting *J2R* and the anti-apoptotic viral gene, *F1L*. This double mutation not only increased the safety of the Copenhagen-strain-derived OVV, but also improved the ability of the OVV double mutation to induce cancer cell death. Another *J2R*-based double-deleted OVV target, B18R, is a type I interferon inhibitor. Additional deletion of B18R rendered the virus carrying interferon-beta with superior tumor selectivity and systemic intravenous efficacy in animal models⁵⁶. The double-mutated vaccinia virus, vvDD-GFP, which has a deletion of *J2R* and *VGF* (an epidermal growth factor homologue encoded by the *C11R* gene that promotes infected cell motility and spread of the viral infection), shows no toxicity in healthy cells, but significant tumor regression is observed at high doses in nude mice⁴⁶. Triple mutation of *VGF*, *O1L* (continuously activates extracellular signal-regulated kinase 1/2 and promotes viral virulence), and *B5R*⁵⁷, as well as *J2R*, *F14.5L*, and *A56R* (encoding hemagglutinin, mediates viral attachment to host cells and inhibits the fusion of infected cells)⁴⁷ give similar results in selective replication and reduced toxicity. Viruses with these mutations are excellent candidates for promoting therapeutic effects owing to superior safety indices. It is interesting to note that OVVs with the quadruple mutation of *J2R*, *A48R* (encoding thymidylate kinase, an enzyme that participates in nucleotide metabolism), *B18R*, and *C11R* maintain tumor selectivity. In a melanoma model, strong viral attenuation, reduced virus dissemination, and effective anti-tumor activity were observed as expected⁵⁸.

All VVs with multiple mutations enhance the selectivity of tumor cells, mitigate virulence, and manifest either unaltered or amplified tumor control. Significant functional improvements owing to multiple deletions have become a popular strategy for OVV development. Recently, quintuple deletions (*C7L-K2L*, *E3L*, *A35R*, *B13R*, and *A66R*) in the VV Tian Tan strain enabled the generation of a more powerful OVV to treat cancer⁵⁹. In addition to improving the selectivity of the OVV, increasing the viral replication ability through gene modification is also important. Using small interfering RNA screening technology, Liu et al.⁶⁰ identified a relationship between the essential necroptosis kinase receptor interacting protein kinase 3 (RIPK3) and the viral inducer of RIPK3 degradation (vIRD). vIRD promotes the ubiquitination and proteasome-mediated degradation of RIPK3, thereby promoting viral replication. This phenomenon has also been observed in a mouse model. It is expected that more efficient OVVs will be designed for cancer therapy in future studies.

Accurate targeting of the virus

Direct injection into the tumor site has a limited systemic impact, whereas intravenous and intraperitoneal infusions have broader effects, but face difficulties in effectively targeting the tumor. The two main factors that promote virus-specific replication in cancer cells are EGFR/Ras pathway activity and cellular TK levels^{44,61,62}. Some VVs lacking TK, such as JX-594⁶³⁻⁶⁷ armed with GM-CSF, GL-ONC1^{68,69}, vvDD^{70,71}, TG6002²³, and T601, have been developed, whereas other VVs that are TK-positive have achieved good clinical results⁷². OV vectors can be genetically modified to target tumor-associated surface markers, such as MUC1⁷³, to improve efficacy.

OVVs have also been used to deliver surface antigens to CAR-T cells⁷⁴ that recognise target cells based on antigen density, as demonstrated by the successful delivery of CD19 to B16 melanoma cells using a TK-disrupted VV⁷⁵. The results were promising, showing a significant improvement in the tumor-killing ability of CAR-T cells and an increase in median survival. Furthermore, OV vectors can be engineered to produce cytokines or chemokines that enhance CAR-T cell function and anti-tumor efficacy, as demonstrated by an engineered VV that produces CXCL11, resulting in increased CXCL11 protein levels and antigen-specific T cell numbers in tumors⁷⁶. These findings suggest that OV vectors hold promise for overcoming the current challenges facing CAR-T cell therapy in solid tumors, and using CAR-T cell guidance enhances VV targeting of tumor cells. Future clinical trials are necessary to validate these findings and to advance the use of OVs in cancer therapy.

Clinical trials of OVVs

In 1995, a phase 3 randomized, double-blind, multi-centre trial of vaccinia melanoma oncolysate (VMO) in patients with stage II melanoma was conducted. There was no difference in the disease-free interval or overall survival between the active specific immunotherapy with VMO and placebo groups⁷⁷. Despite this setback, further research on VVs for cancer immunotherapy has continued, with modifications aimed at improving the effectiveness of treatment based on the physiologic characteristics of the virus and previous experience.

Given the role of cytokines and chemokines in the inflammatory environment of the TME, an OVV (JX-594) was modified to include GM-CSF. In 2013, a randomised phase II trial involving JX-594 in liver cancer showed that the subject survival duration was significantly dependent on the dosage (median survival of 14.1 months *vs.* 7 months on high and low doses, respectively; hazard ratio = 0.39; $P = 0.020$)⁶⁷. Recently, a phase I/II study of JX-594 was conducted in combination with an ICI for refractory metastatic colorectal cancer (mCRC). In this study there was no significant difference in the median progression-free survival (PFS) between the PexaVec/durvalumab/tremelimumab cohorts and the Pexa Vec/durvalumab cohorts (2.3 months *vs.* 2.1 months; $P = 0.57$)⁶⁵, but the number of Ki67+CD8+ T cells increased in peripheral blood mononuclear cells. Further studies are required to determine the potential clinical activity of the combination of VV and ICIs.

To improve immunogenicity, VVs have been armed with genes encoding specific TAAs and co-stimulatory molecules. In 1996, a recombinant vaccinia virus (TA-HPV) was engineered to encode human papillomavirus (HPV) types 16, 18, E6, and E7 proteins, and used as immunotherapy for cervical cancer. Although the clinical effectiveness was limited by the sample size, 2 patients remained clinically well at 15 and 21 months post-vaccination⁷⁸. Later, a phase I trial for metastatic melanoma patients was conducted using a recombinant vaccinia virus expressing B7.1 (rV-B7.1), which showed that rV-B7.1 induced objective tumor regression, anti-VV antibody responses, and T cell responses against defined melanoma antigens⁷⁹. Kantoff et al.⁸⁰ conducted a phase II randomised controlled trial of PROSTVAC-VF in prostate cancer in 2010 that was comprised of two recombinant viral vectors, each encoding a transgene for PSA and three immune co-stimulatory molecules (B7.1, ICAM-1, and LFA-3). The PROSTVAC-VF group had better overall survival 3 years post-study, with 25 (30%) of 82 treated patients alive versus 7 (17%) of 40 control patients alive, and longer median survival by 8.5 months (25.1 months for treated patients *vs.* 16.6 months for controls)⁸¹.

Based on recent preclinical research and clinical trials (Table 3), OVVs were shown to have great promise as a platform for various approaches to eliminate cancers. Genetic modification of these viruses can significantly enhance their ability to control tumors, making it a promising method for improving therapeutic efficacy and overcoming some of the clinical limitations.

Production of neutralizing antibodies

Concerns about the efficacy of the smallpox vaccine in older patients vaccinated at a young age remain a general issue for VV. The antiviral response, particularly the production of neutralising antibodies, may persist in the TME. In a phase I study, it was shown that individuals > 45 years of age displayed minimal anti-VV antibody levels before treatment with VV. Although neutralising antibodies were shown to increase rapidly within 3–6 weeks of treatment, OV proliferation, replication, and tumoricidal properties were not affected^{40,82}. Research from decades ago showed that the unique biology of VV allows for the production of ‘invisible’ particles (EEVs) that can safely travel in the blood in the presence of neutralising antibodies and complement. Therefore, repeated intravenous injections may theoretically serve as an effective therapeutic tool for enhancing immunity^{83,84}.

Table 3 Key clinical trials of OVVs from ClinicalTrials.gov

Name	Genetic modifications	Enrollment	Interventions	Indication	Clinical responses	Status	NCT number
Pexa-Vec (JX-594)	Wyeth strain (Δ TK)	34	+Drug: Durvalumab (anti-PD1); Tremelimumab (anti-CTLA-4)	Colorectal cancer	Median PFS 2.3 months (PexaVec/durvalumab/tremelimumab cohorts) vs. 2.1 months (the PexaVec/durvalumab cohorts)	Phase I; Phase II	NCT03206073 ⁶⁵
	Transgenic expression of GM-CSF and β -galactosidase	10	Monotherapy	Melanoma	DOR and PFS were not assessable since most patients went off study within 6 weeks	Completed Phase I; Phase II	NCT00429312 ¹⁰⁹
		15	Monotherapy	Colorectal carcinoma	PFS and OS of all eligible patients were 61 days and 10.3 months	Completed Phase II	NCT01469611 ⁶³
		23	+Drug: Sorafenib	Carcinoma, hepatocellular	FGF-2 stimulated JX-594 activation in endothelial cells; JX-594 was able to specifically target and infect TECs	Completed Phase II	NCT01171651 ¹¹⁰
		14	Monotherapy	Neoplasms, liver	Median survival for all 14 patients was 9 months	Completed Phase I	NCT00629759 ⁴⁵
		6	Monotherapy	Neuroblastoma	4 of 6 patients had a SD and 2 had PD in the injected target lesion	Completed Phase I	NCT01169584 ¹¹¹
		30	Monotherapy	Carcinoma, hepatocellular	Median OS 14.1 months (high dose) vs. 6.7 months (low dose)	Completed Phase II	NCT00554372 ⁶⁷
		129	Monotherapy	Carcinoma, hepatocellular	Median OS 4.2 months (Pexa-Vec+BSC) vs. 4.4 months (BSC)	Completed Phase II	NCT01387555 ¹¹²
		23	Monotherapy	Melanoma	Dose-related antitumor activity was correlated with delivery and replication of JX-594	Completed Phase I; Phase II	NCT00625456 ⁴⁰
		64	+Drug: Chemotherapy or bevacizumab (anti-EGFR)	Ovarian cancer	Median OS 18.5 months (platinum-resistant group) vs. 14.7 months (platinum-refractory group)	Completed Phase I; Phase II	NCT02759588 ¹¹³
GL-ONC1 (GLV-1h68)	Lister strain (Δ FI4.5L, Δ A56R and Δ TK)	19	Monotherapy	Cancer of the head and neck	With median follow-up of 30 months, 1-year (2-year) PFS and OS were 74.4% (64.1%) and 84.6% (69.2%), respectively	Completed Phase I	NCT01584284 ⁶⁹
	Transgenic expression of Luc-GFP, β -glucuronidase	9	Monotherapy	Peritoneal carcinomatosis	GL-ONC1 was well tolerated when administered into the peritoneal cavity of patients with advanced stage peritoneal carcinomatosis	Completed Phase I; Phase II	NCT01443260 ⁶⁸

Table 3 Continued

Name	Genetic modifications	Enrolment	Interventions	Indication	Clinical responses	Status	NCT number
TroVax	Modified vaccinia virus Ankara Transgenic expression of tumor antigen 5T4	733	+Drug: Sunitinib	Renal cell cancer	No significant difference in OS was evident in the two treatment arms; The magnitude of the 5T4-specific antibody response induced by vaccination with MVA-5T4 was associated with enhanced patient survival	Completed Phase II/III	NCT00397345 ¹⁴
TG4010	Modified vaccinia virus Ankara Transgenic expression of MUC1 and IL-2	222	+Drug: First-line chemotherapy	Non-small-cell lung carcinoma	Median PFS 5.9 months (TG4010 group) vs. 5.1 months (the placebo group)	Terminated Phase II/III	NCT01383148 ¹⁵
PROSTVAC	Wyeth strain (Δ TK) Transgenic expression of B7.1, ICAM-1, and LFA-3	120	Monotherapy	Prostate cancer	PROSTVAC-VF immunotherapy was well-tolerated and associated with a 44% reduction in the death rate and an 8.5-month improvement in the median OS	Completed Phase II	NCT00078585 ⁸⁰
PANVAC	Wyeth strain (Δ TK) Transgenic expression of CEA, MUC-1, B7.1, ICAM-1, and LFA3	48	+Drug: Docetaxel	Breast cancer	Median PFS 7.9 months (combination group) vs. 3.9 months (control group)	Completed Phase II	NCT00179309 ¹¹⁶
MVA-5T4	Modified vaccinia virus Ankara Transgenic expression of tumor antigen 5T4	25	Monotherapy	Renal cell cancer	Vaccination with MVA-5T4 did not improve ORR of IL-2 therapy, but did result in SD associated with an increase in the ratio of 5T4-specific effector-to-regulatory T cells in selected patients.	Completed Phase II	ISRCTN 83977250 ¹¹⁷
rV-B7.1	Wyeth strain (Δ TK) Transgenic expression of B7.1	12	Monotherapy	Melanoma	Melanoma patients injected with rV-B7.1 develop anti-vaccinia virus antibody responses and T cell responses against defined melanoma antigens	Completed Phase I	NCT00004148 ⁷⁹
IN rVV	Copenhagen strain (Δ TK and Δ I4L)	15	Monotherapy	Melanoma	Of 10 remaining patients 7 showed evidence of induction of CTLs directed against at least one epitope	Completed Phase I/II	Not found ¹¹⁷

PFS, progression-free survival; DOR, durability of responses; TECs, tumor-associated endothelial cells; SD, stable disease; PD, progressive disease; BSC, basic support care; ORR, objective response rates; CTLs, cytotoxic T lymphocytes. Some clinical trials without publicly available results have not been included in the table.

Drug dosage

An appropriate dosage, based on efficacy and safety, is critical for achieving excellent curative effects. The hostile TME, which is characterised by hypoxia and antiviral reactions, makes survival at low doses challenging^{9,37,85}. Elevating the concentration of specific cytokines around tumors can indirectly prolong viral survival in tumors treated with low doses^{86,87}. Preclinical studies have demonstrated that increased concentrations of IL-10 and IL-23 in the TME can promote viral replication, prolong viral survival, and inhibit immune responses. In a phase I trial of intra-tumoral injection into solid tumors, JX-594 was well-tolerated, endogenous cytokine levels increased in a dose-dependent manner⁴⁰, and challenges associated with high-dose administration were well-documented. An open-label, three-step, dose-escalating, single-centre, phase Ib study involving Olvi-Vec, a modified vaccine virus, was conducted. To assess safety by analysing adverse events, Olvi-Vec was divided into three dose groups, and each group was administered intraperitoneally⁸². Surprisingly, no differences in toxicity were observed between the three dose groups. Of the 11 subjects in the study, stable disease was observed in 7 individuals, with an overall response rate of 9% (1/11) and a median PFS of 15.7 weeks (95% confidence interval: 5.7–34.5). In another phase II clinical trial involving JX-594, some patients in the high-dose group had symptoms of lymphopenia and were evaluated for serum transaminase concentrations (2-week duration); however, despite these adverse effects, the high-dose treatment group did not show reduced efficacy, exhibiting longer-term survival benefits than the low-dose cohort (median survival of 14.1 months *vs.* 6.7 months, hazard ratio = 0.39; $P = 0.020$)⁶⁷.

As many genes encoded by the VV genome have unknown functions, unpredictable challenges remain. In addition, although VV prefers cells with rapid cell cycle progression, similar to cancer cells, VV can also infect various cell types, including somatic cells⁸⁸. Therefore, modifying viral strains with targeted mutations in viral genes related to nucleotide metabolism, apoptosis, inflammation, chemokines, and interferon signalling can improve tumor selectivity, safety, viral replication, and the ability to modulate immune responses, while maintaining viral replication and oncolytic capacity^{6,55,89-91}.

Discussion

Oncolytic virotherapy holds promise as a cancer treatment, but often exhibits limited therapeutic efficacy when used alone, which is a persistent concern across the field of cancer therapy. To address this issue, innovative modifications and combination therapies are required to improve the effectiveness of OVVs. In this review we discussed the advantages and disadvantages of OVVs and highlighted several critical considerations for future development.

The safety of the VV for human use has been established based on its previous application as a vaccine against smallpox and its ability to replicate exclusively in the cytoplasm, precluding its integration into the host genome. Another significant advantage of VV is its capacity for intravenous administration, which sets it apart from many other OVVs that are limited to intra-tumoral injections. This approach is impractical for patients with superficial tumors and multifocal metastases. While the intravenous infusion of VV may be susceptible to host antiviral immune response, a recent study using transient pharmacologic inhibition of leukocyte-enriched phosphoinositide 3-kinase δ (PI3K δ) demonstrated successful improvement of VV delivery to tumors in mouse models⁹².

Despite the widespread use of OVVs in preclinical and clinical studies, several obstacles remain. The TME is the microecology upon which tumor cells depend for survival and where OVVs exhibit anti-tumor effects, making the TME crucial for both tumors and viruses. Owing to its significant immunogenicity, the VV is quickly eliminated by the host's immune system, which restricts its oncolytic potential and replication. The modification of viral vectors is required to reduce immunogenicity and improve immune evasion. Additionally, the large size of the VV necessitates stringent sterile conditions for its production and preparation. Therefore, oncolytic virotherapy should be tailored to specific cancer types by developing biomarker panels to determine the sensitivity of tumors to this therapeutic approach.

The VV genome encodes approximately 250 genes involved in virulence and suppression of the immune system. Removing specific genes and inserting immunostimulatory genes or other genes into the viral genome are fundamental and promising methods for constructing recombinant viruses. The sizeable viral genome of the VV allows for the introduction of up to 50 kb of foreign genes, making VV a productive therapeutic tool for multiple gene delivery, including genes encoding




Figure 2 Scheme of engineered oncolytic vaccinia virus (OVV) and mechanisms of enhanced anti-tumor activity. OVVs armed with cytokines or tumor suppressor genes enhance immune cell infiltration, damage the vascular bed, inhibit suppressive immune cells (such as MDSCs and Tregs), and induce cell apoptosis and autophagy, thus resulting in the release of tumor-associated antigens. OVVs express immunotherapeutic genes, including those encoding immune checkpoint inhibitors, antibodies, and bispecific antibodies, which exert potent and specific cytotoxicity in a variety of tumor models by enhancing immunotherapeutic effects. Modified OVVs with a thymidine kinase (TK) deletion, the insertion of a suicide gene, and expression of siRNA have increased oncolytic properties and safety.

antibodies^{31,93}, cytokines^{57,94-96}, chemokines^{97,98} and ligands⁹⁹ (Figure 2). Oncolytic virotherapy has the potential to be an attractive combination partner with other immunotherapies based on the mechanisms of tumor resistance to immune-mediated clearance. This feature provides an intense synergistic effect that maximises the benefits of combination therapy, as reported in previous studies. The OVV represents an ideal element for combination therapy because of its good safety profile and multiple anti-tumor mechanisms. Viral infection and capacity to lyse tumors converts 'cold' tumors into 'hot' tumors

and enhances the infiltration and recruitment of immune cells into the TME (Figure 3).

An OVV combined with immune checkpoint inhibition exhibits a potent synergistic effect. Moreover, OVVs armed with monoclonal antibodies⁹³, bispecific antibodies¹⁰⁰, and functional ligand-specific⁹⁹ have also been demonstrated to have anti-tumor effects in a series of preclinical studies. Deliberate therapeutic regimens are necessary, however, for combined therapies because ICIs can hinder VV replication¹⁰¹. It is crucial to achieve both effects for maximum results, while




Figure 3 Tumor microenvironment remodelling induced by OVV. The OVV can be administered intravenously, after which it selectively infects and replicates in tumor cells. OVV is then released within the tumor microenvironment (TME), resulting in a change in the TME from the original 'cold' state (immunosuppression) to a 'hot' state (immune activation) due to the infiltration of immune cells. Macrophages and dendritic cells engulf OVV-infected tumor cells and present antigens to lymphocytes. CD8+ T lymphocytes work in coordination with immune checkpoint inhibitors or immunotherapeutic antibodies released by OVV-infected tumor cells and eliminate the tumor cells. The armed antibody with an Fc fragment results in the activation of natural killer (NK) cells, thereby stimulating the antibody-dependent cellular cytotoxicity of NK cells. DAMPs, danger-associated molecular patterns; TAAs, tumor-associated antigens; Treg cells, regulatory T cells.

avoiding the negative effect of the armed gene in the OVV. Simultaneous treatment with an OVV and ICIs results in more effective therapeutic outcomes than single treatments⁹⁸; however, integrating genes expressing ICIs into the viral genome may be an ideal approach for combination therapy with OVVs¹⁰²⁻¹⁰⁸.

Overall, the effectiveness of oncolytic VV-based therapies has been demonstrated in a wide range of cancer types in many studies. Recently, various strategies that can be synergistically

implemented for maximum efficacy have been developed. Among them, combination therapies with immunotherapy could be a very promising approach to improve therapeutic outcomes.

Grant support

This work was supported by the National Natural Science Foundation of China (Grant No. 81830006) and the Science

Technology Department of Zhejiang Province (Grant No. 2021C03117).

Conflict of interest statement

No potential conflicts of interest are disclosed.

Author contributions

Conceived and designed the analysis: Yunhua Liu and Wenbin Qian.

Wrote the manuscript: Mengyuan Li, Minghuan Zhang and Qian Ye.

References

- Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. *Pharmacol Ther.* 2021; 221: 107753.
- Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. *Immunity.* 2019; 51: 27-41.
- Kiyotani K, Toyoshima Y, Nakamura Y. Personalized immunotherapy in cancer precision medicine. *Cancer Biol Med.* 2021; 18: 955-65.
- La-Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB. Immune checkpoint inhibitors: new insights and current place in cancer therapy. *Pharmacotherapy.* 2015; 35: 963-76.
- Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. *Clin Ther.* 2015; 37: 764-82.
- Buller RM, Chakrabarti S, Cooper JA, Twardzik DR, Moss B. Deletion of the vaccinia virus growth factor gene reduces virus virulence. *J Virol.* 1988; 62: 866-74.
- Andtbacka RHI, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. *J Clin Oncol.* 2015; 33: 2780-8.
- Russell SJ, Peng K-W, Bell JC. Oncolytic virotherapy. *Nat Biotechnol.* 2012; 30: 658-70.
- Pipiya T, Sauthoff H, Huang YQ, Chang B, Cheng J, Heitner S, et al. Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression. *Gene Ther.* 2005; 11: 911-7.
- Cattaneo R, Russell SJ. How to develop viruses into anticancer weapons. *PLoS Pathog.* 2017; 13: e1006190.
- Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy. *Nat Rev Immunol.* 2018; 18: 498-513.
- Fenner F. A successful eradication campaign. Global eradication of smallpox. *Rev Infect Dis.* 1982; 5: 916-30.
- Grigg C, Blake Z, Gartrell R, Sacher A, Taback B, Saenger Y. Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers. *Semin Oncol.* 2016; 43: 638-46.
- Martin NT, Bell JC. Oncolytic virus combination therapy: killing one bird with two stones. *Mol Ther.* 2018; 26: 1414-22.
- Raja J, Ludwig JM, Gettinger SN, Schalper KA, Kim HS. Oncolytic virus immunotherapy: future prospects for oncology. *J Immunother Cancer.* 2018; 6: 140.
- Kim M, Nitschké M, Sennino B, Murer P, Schriver BJ, Bell A, et al. Amplification of oncolytic vaccinia virus widespread tumor cell killing by sunitinib through multiple mechanisms. *Cancer Res.* 2018; 78: 922-37.
- Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. *Nat Rev Drug Discov.* 2015; 14: 642-62.
- Wang X, Zhou N, Liu T, Jia X, Ye T, Chen K, et al. Oncolytic vaccinia virus expressing white-spotted charr lectin regulates antiviral response in tumor cells and inhibits tumor growth in vitro and in vivo. *Mar Drugs.* 2021; 19: 292.
- Chen W, Fan W, Ru G, Huang F, Lu X, Zhang X, et al. Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer. *Oncol Rep.* 2019; 41: 67-76.
- Hu J, Wang H, Gu J, Liu X, Zhou X. Trail armed oncolytic poxvirus suppresses lung cancer cell by inducing apoptosis. *Acta Biochim Biophys Sin (Shanghai).* 2018; 50: 1018-27.
- Inoue T, Byrne T, Inoue M, Tait ME, Wall P, Wang A, et al. Oncolytic vaccinia virus gene modification and cytokine expression effects on tumor infection, immune response, and killing. *Mol Cancer Ther.* 2021; 20: 1481-94.
- Lei W, Wang S, Xu N, Chen Y, Wu G, Zhang A, et al. Enhancing therapeutic efficacy of oncolytic vaccinia virus armed with Beclin-1, an autophagic gene in leukemia and myeloma. *Biomed Pharmacother.* 2020; 125: 110030.
- Foloppe J, Kempf J, Futin N, Kintz J, Cordier P, Pichon C, et al. The enhanced tumor specificity of TG6002, an armed oncolytic vaccinia virus deleted in two genes involved in nucleotide metabolism. *Mol Ther Oncolytics.* 2019; 14: 1-14.
- Li J, O'Malley M, Urban J, Sampath P, Guo ZS, Kalinski P, et al. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. *Mol Ther.* 2011; 19: 650-7.
- Zuo S, Wei M, Xu T, Kong L, He B, Wang S, et al. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade. *J Immunother Cancer.* 2021; 9: e002843.
- Tian L, Xu B, Teng K-Y, Song M, Zhu Z, Chen Y, et al. Targeting Fc receptor-mediated effects and the "don't eat me" signal with an oncolytic virus expressing an anti-CD47 antibody to treat metastatic ovarian cancer. *Clin Cancer Res.* 2022; 28: 201-14.
- Liang J, Zhao X. Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development. *Cancer Biol Med.* 2021; 18: 352-71.

28. Giustarini G, Pavesi A, Adriani G. Nanoparticle-based therapies for turning cold tumors hot: how to treat an immunosuppressive tumor microenvironment. *Front Bioeng Biotechnol.* 2021; 9: 689245.
29. West NR, McCuaig S, Franchini F, Powrie F. Emerging cytokine networks in colorectal cancer. *Nat Rev Immunol.* 2015; 15: 615-29.
30. Wei M, Zuo S, Chen Z, Qian P, Zhang Y, Kong L, et al. Oncolytic vaccinia virus expressing a bispecific T-cell engager enhances immune responses in EpCAM positive solid tumors. *Front Immunol.* 2022; 13: 1017574.
31. Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song X-T. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. *Mol Ther.* 2014; 22: 102-11.
32. Lei W, Ye Q, Hao Y, Chen J, Huang Y, Yang L, et al. CD19-targeted BiTE expression by an oncolytic vaccinia virus significantly augments therapeutic efficacy against B-cell lymphoma. *Blood Cancer J.* 2022; 12: 35.
33. Hou W, Sampath P, Rojas JJ, Thorne SH. Oncolytic virus-mediated targeting of PGE2 in the tumor alters the immune status and sensitizes established and resistant tumors to immunotherapy. *Cancer Cell.* 2016; 30: 108-19.
34. Rivadeneira DB, DePeaux K, Wang Y, Kulkarni A, Tabib T, Menk AV, et al. Oncolytic viruses engineered to enforce leptin expression reprogram tumor-infiltrating T cell metabolism and promote tumor clearance. *Immunity.* 2019; 51: 548-560.e4.
35. Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, et al. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. *J Immunother Cancer.* 2019; 7: 6.
36. Yang Z, Gray M, Winter L. Why do poxviruses still matter? *Cell Biosci.* 2021; 11: 96.
37. Moss B. Poxvirus DNA replication. *Cold Spring Harb Perspect Biol.* 2013; 5: a010199.
38. PFAU CJ, McCREA JF. Release of deoxyribonucleic acid from vaccinia virus by 2-mercaptoethanol and pronase. *Nature.* 1962; 194: 894-5.
39. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. *Immunity.* 2008; 28: 710-22.
40. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. *Nature.* 2011; 477: 99-102.
41. Handa Y, Durkin CH, Dodding MP, Way M. Vaccinia virus F11 promotes viral spread by acting as a PDZ-containing scaffolding protein to bind myosin-9A and inhibit RhoA signaling. *Cell Host Microbe.* 2013; 14: 51-62.
42. Smith GL, Vanderplasschen A. Extracellular enveloped vaccinia virus. Entry, egress, and evasion. *Adv Exp Med Biol.* 1998; 440: 395-414.
43. Doceul V, Hollinshead M, van der Linden L, Smith GL. Repulsion of superinfecting virions: a mechanism for rapid virus spread. *Science.* 2010; 327: 873-6.
44. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. *Nat Rev Cancer.* 2009; 9: 64-71.
45. Park B-H, Hwang T, Liu T-C, Sze DY, Kim JS, Kwon HC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. *Lancet Oncol.* 2008; 9: 533-42.
46. McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. *Cancer Res.* 2001; 61: 8751-7.
47. Zhang Q, Yu YA, Wang E, Chen N, Danner RL, Munson PJ, et al. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. *Cancer Res.* 2007; 67: 10038-46.
48. Zhang Z, Dong L, Zhao C, Zheng P, Zhang X, Xu J. Vaccinia virus-based vector against infectious diseases and tumors. *Hum Vaccin Immunother.* 2021; 17: 1578-85.
49. Deng L, Fan J, Guo M, Huang B. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9. *Cancer Lett.* 2016; 372: 251-7.
50. Benhnia MR, McCausland MM, Laudenslager J, Granger SW, Rickert S, Koriazova L, et al. Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5. *J Virol.* 2009; 83: 12355-67.
51. Benhnia MR, McCausland MM, Moyron J, Laudenslager J, Granger S, Rickert S, et al. Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. *J Virol.* 2009; 83: 1201-15.
52. Benhnia MR, Maybeno M, Blum D, Aguilar-Sino R, Matho M, Meng X, et al. Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine. *J Virol.* 2013; 87: 1569-85.
53. Slabaugh M, Roseman N, Davis R, Mathews C. Vaccinia virus-encoded ribonucleotide reductase-sequence conservation of the gene for the small subunit and its amplification in hydroxyurea-resistant mutants. *J Virol.* 1988; 62: 519-27.
54. Potts KG, Irwin CR, Favis NA, Pink DB, Vincent KM, Lewis JD, et al. Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models. *EMBO Mol Med.* 2017; 9: 638-54.
55. Pelin A, Foloppe J, Petryk J, Singaravelu R, Hussein M, Gossart F, et al. Deletion of apoptosis inhibitor FIL in vaccinia virus increases safety and oncolysis for cancer therapy. *Mol Ther Oncolytics.* 2019; 14: 246-52.
56. Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. *PLoS Med.* 2007; 4: e353.
57. Nakao S, Arai Y, Tasaki M, Yamashita M, Murakami R, Kawase T, et al. Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade. *Sci Transl Med.* 2020; 12: eaax7992.

58. Mejías-Pérez E, Carreño-Fuentes L, Esteban M. Development of a safe and effective vaccinia virus oncolytic vector WR-Δ4 with a set of gene deletions on several viral pathways. *Mol Ther Oncolytics*. 2018; 8: 27-40.
59. Li Y, Zhu Y, Chen S, Li W, Yin X, Li S, et al. Generation of an attenuated tiantan vaccinia virus strain by deletion of multiple genes. *Front Cell Infect Microbiol*. 2017; 7: 462.
60. Liu Z, Nailwal H, Rector J, Rahman MM, Sam R, McFadden G, et al. A class of viral inducer of degradation of the necroptosis adaptor RIPK3 regulates virus-induced inflammation. *Immunity*. 2021; 54: 247-258.e7.
61. Yang H, Kim SK, Kim M, Reche PA, Morehead TJ, Damon IK, et al. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. *J Clin Invest*. 2005; 115: 379-87.
62. Buller RM, Smith GL, Cremer K, Notkins AL, Moss B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. *Nature*. 1985; 317: 813-5.
63. Park SH, Breitbach CJ, Lee J, Park JO, Lim HY, Kang WK, et al. Phase 1b trial of biweekly intravenous Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus in colorectal cancer. *Mol Ther*. 2015; 23: 1532-40.
64. Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. *Mol Ther*. 2012; 20: 749-58.
65. Monge C, Xie C, Myojin Y, Coffman K, Hrones DM, Wang S, et al. Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer. *J Immunother Cancer*. 2023; 11: e005640.
66. Liu T-C, Hwang T, Park B-H, Bell J, Kirn DH. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. *Mol Ther*. 2008; 16: 1637-42.
67. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. *Nat Med*. 2013; 19: 329-36.
68. Lauer UM, Schell M, Beil J, Berchtold S, Koppenhöfer U, Glatzle J, et al. Phase I study of oncolytic vaccinia virus GL-ONC1 in patients with peritoneal carcinomatosis. *Clin Cancer Res*. 2018; 24: 4388-98.
69. Mell LK, Brumund KT, Daniels GA, Advani SJ, Zakeri K, Wright ME, et al. Phase I trial of intravenous oncolytic vaccinia virus (GL-ONC1) with cisplatin and radiotherapy in patients with locoregionally advanced head and neck carcinoma. *Clin Cancer Res*. 2017; 23: 5696-702.
70. Downs-Canner S, Guo ZS, Ravindranathan R, Breitbach CJ, O'Malley ME, Jones HL, et al. Phase 1 study of intravenous oncolytic poxvirus (vvDD) in patients with advanced solid cancers. *Mol Ther*. 2016; 24: 1492-501.
71. Zeh HJ, Downs-Canner S, McCart JA, Guo ZS, Rao UN, Ramalingam L, et al. First-in-man study of Western Reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity. *Mol Ther*. 2015; 23: 202-14.
72. Minev BR, Lander E, Feller JF, Berman M, Greenwood BM, Minev I, et al. First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells. *J Transl Med*. 2019; 17: 271.
73. Remy-Ziller C, Thioudellet C, Hortelano J, Gantzer M, Nourtier V, Claudepierre MC, et al. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model. *Hum Vaccin Immunother*. 2018; 14: 140-5.
74. Zhang S, Rabkin SD. The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy? *Expert Opin Drug Discov*. 2021; 16: 391-410.
75. Aalipour A, Le Boeuf F, Tang M, Murty S, Simonetta F, Lozano AX, et al. Viral delivery of CAR targets to solid tumors enables effective cell therapy. *Mol Ther Oncolytics*. 2020; 17: 232-40.
76. Moon EK, Wang L-CS, Bekdache K, Lynn RC, Lo A, Thorne SH, et al. Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines. *Oncoimmunology*. 2018; 7: e1395997.
77. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, et al. A phase III randomized, double-blind, multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. *Cancer*. 1995; 75: 34-42.
78. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. *Lancet*. 1996; 347: 1523-27.
79. Kaufman HL, Deraffe G, Mitcham J, Moroziewicz D, Cohen SM, Hurst-Wicker KS, et al. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. *J Clin Invest*. 2005; 115: 1903-12.
80. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. *J Clin Oncol*. 2010; 28: 1099-105.
81. Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. *Cancer Immunol Immunother*. 2010; 59: 663-74.
82. Manyam M, Stephens AJ, Kennard JA, LeBlanc J, Ahmad S, Kendrick JE, et al. A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer. *Gynecol Oncol*. 2021; 163: 481-9.
83. Vanderplassen A, Mathew E, Hollinshead M, Sim RB, Smith GL. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. *Proc Natl Acad Sci U S A*. 1998; 95: 7544-9.

84. Pittman PR, Hahn M, Lee HS, Koca C, Samy N, Schmidt D, et al. Phase 3 efficacy trial of modified vaccinia Ankara as a vaccine against smallpox. *N Engl J Med*. 2019; 381: 1897-908.
85. Hiley CT, Yuan M, Lemoine NR, Wang Y. Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumors. *Gene Ther*. 2010; 17: 281-7.
86. Chen L, Chen H, Ye J, Ge Y, Wang H, Dai E, et al. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation. *Theranostics*. 2021; 11: 6668-81.
87. Chard LS, Maniati E, Wang P, Zhang Z, Gao D, Wang J, et al. A vaccinia virus armed with interleukin-10 is a promising therapeutic agent for treatment of murine pancreatic cancer. *Clin Cancer Res*. 2015; 21: 405-16.
88. Chan WM, McFadden G. Oncolytic poxviruses. *Annu Rev Virol*. 2014; 1: 119-41.
89. Nakatake M, Kurosaki H, Kuwano N, Horita K, Ito M, Kono H, et al. Partial deletion of glycoprotein B5R enhances vaccinia virus neutralization escape while preserving oncolytic function. *Mol Ther Oncolytics*. 2019; 14: 159-71.
90. Di Pilato M, Mejias-Pérez E, Sorzano COS, Esteban M. Distinct roles of vaccinia virus NF- κ B inhibitor proteins A52, B15, and K7 in the immune response. *J Virol*. 2017; 91: e00575-17.
91. Umer BA, Noyce RS, Franczak BC, Shenouda MM, Kelly RG, Favis NA, et al. Deciphering the immunomodulatory capacity of oncolytic vaccinia virus to enhance the immune response to breast cancer. *Cancer Immunol Res*. 2020; 8: 618-31.
92. Ferguson MS, Chard Dunmall LS, Gangeswaran R, Marelli G, Tysome JR, Burns E, et al. Transient inhibition of PI3K δ enhances the therapeutic effect of intravenous delivery of oncolytic vaccinia virus. *Mol Ther*. 2020; 28: 1263-75.
93. Woo Y, Zhang Z, Yang A, Chaurasiya S, Park AK, Lu J, et al. Novel chimeric immuno-oncolytic virus CF33-hNIS-antiPDL1 for the treatment of pancreatic cancer. *J Am Coll Surg*. 2020; 230: 709-17.
94. Liu W, Dai E, Liu Z, Ma C, Guo ZS, Bartlett DL. In situ therapeutic cancer vaccination with an oncolytic virus expressing membrane-tethered IL-2. *Mol Ther Oncolytics*. 2020; 17: 350-60.
95. Deng L, Yang X, Ding Y, Fan J, Peng Y, Xu D, et al. Oncolytic therapy with vaccinia virus carrying IL-24 for hepatocellular carcinoma. *Virol J*. 2022; 19: 44.
96. Ge Y, Wang H, Ren J, Liu W, Chen L, Chen H, et al. Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety. *J Immunother Cancer*. 2020; 8: e000710.
97. Li F, Sheng Y, Hou W, Sampath P, Byrd D, Thorne S, et al. CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency. *J Immunother Cancer*. 2020; 8: e000131.
98. Liu Z, Ravindranathan R, Kalinski P, Guo ZS, Bartlett DL. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. *Nat Commun*. 2017; 8: 14754.
99. Wang G, Kang X, Chen KS, Jehng T, Jones L, Chen J, et al. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. *Nat Commun*. 2020; 11: 1395.
100. Yang X, Zhang X, Fu ML, Weichselbaum RR, Gajewski TF, Guo Y, et al. Targeting the tumor microenvironment with interferon- β bridges innate and adaptive immune responses. *Cancer Cell*. 2014; 25: 37-48.
101. Rojas JJ, Sampath P, Hou W, Thorne SH. Defining effective combinations of immune checkpoint blockade and oncolytic virotherapy. *Clin Cancer Res*. 2015; 21: 5543-51.
102. Ballesteros-Briones MC, Martisova E, Casales E, Silva-Pilipich N, Buñuales M, Galindo J, et al. Short-term local expression of a PD-L1 blocking antibody from a self-replicating RNA vector induces potent antitumor responses. *Mol Ther*. 2019; 27: 1892-905.
103. Wu T, Dai Y. Tumor microenvironment and therapeutic response. *Cancer Lett*. 2017; 387: 61-8.
104. Huang Y, Lv S-Q, Liu P-Y, Ye ZL, Yang H, Li LF, et al. A SIRP α -Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer. *Mol Oncol*. 2020; 14: 657-68.
105. Zhang Y, Zhang H, Wei M, Mou T, Shi T, Ma Y, et al. Recombinant adenovirus expressing a soluble fusion protein PD-1/CD137L subverts the suppression of CD8+ T cells in HCC. *Mol Ther*. 2019; 27: 1906-18.
106. Zhu Y, Hu X, Feng L, Yang Z, Zhou L, Duan X, et al. Enhanced therapeutic efficacy of a novel oncolytic herpes simplex virus type 2 encoding an antibody against programmed cell death 1. *Mol Ther Oncolytics*. 2019; 15: 201-13.
107. Passaro C, Alayo Q, de Laura I, McNulty J, Grauwet K, Ito H, et al. Arming an oncolytic herpes simplex virus type 1 with a single-chain fragment variable antibody against PD-1 for experimental glioblastoma therapy. *Clin Cancer Res*. 2019; 25: 290-9.
108. Hamilton JR, Vijayakumar G, Palese P. A recombinant antibody-expressing influenza virus delays tumor growth in a mouse model. *Cell Rep*. 2018; 22: 1-7.
109. Hwang T-H, Moon A, Burke J, Ribas A, Stephenson J, Breitbach CJ, et al. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. *Mol Ther*. 2011; 19: 1913-22.
110. Breitbach CJ, Arulanandam R, de Silva N, Thorne SH, Patt R, Daneshmand M, et al. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. *Cancer Res*. 2013; 73: 1265-75.
111. Cripe TP, Ngo MC, Geller JI, Louis CU, Currier MA, Racadio JM, et al. Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients. *Mol Ther*. 2015; 23: 602-8.
112. Moehler M, Heo J, Lee HC, Tak WY, Chao Y, Paik SW, et al. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). *Oncoimmunology*. 2019; 8: 1615817.
113. Holloway RW, Mendivil AA, Kendrick JE, Abaid LN, Brown JV, LeBlanc J, et al. Clinical activity of olvimulogene nanivacirepvec-primed immunotherapy in heavily pretreated patients with platinum-resistant or platinum-refractory ovarian cancer: the

- nonrandomized phase 2 VIRO-15 clinical trial. *JAMA Oncol.* 2023; 9: 903-8.
114. Amato RJ, Hawkins RE, Kaufman HL, Thompson JA, Tomczak P, Szczylik C, et al. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. *Clin Cancer Res.* 2010; 16: 5539-47.
115. Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, et al. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. *Lancet Oncol.* 2016; 17: 212-23.
116. Gulley JL, Arlen PM, Tsang K-Y, Yokokawa J, Palena C, Poole DJ, et al. Pilot study of vaccination with recombinant

- CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. *Clin Cancer Res.* 2008; 14: 3060-9.
117. Kaufman HL, Taback B, Sherman W, Kim DW, Shingler WH, Moroziewicz D, et al. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. *J Transl Med.* 2009; 7: 2.

Cite this article as: Li M, Zhang M, Ye Q, Liu Y, Qian W. Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review. *Cancer Biol Med.* 2023; x: xx-xx. doi: 10.20892/j.issn.2095-3941.2023.0202